Self-assembling ferritin-dendrimer nanoparticles for targeted delivery of nucleic acids to myeloid leukemia cells.

Journal of Nanobiotechnology
Federica PalombariniAlberto Boffi

Abstract

In recent years, the use of ferritins as nano-vehicles for drug delivery is taking center stage. Compared to other similar nanocarriers, Archaeoglobus fulgidus ferritin is particularly interesting due to its unique ability to assemble-disassemble under very mild conditions. Recently this ferritin was engineered to get a chimeric protein targeted to human CD71 receptor, typically overexpressed in cancer cells. Archaeoglobus fulgidus chimeric ferritin was used to generate a self-assembling hybrid nanoparticle hosting an aminic dendrimer together with a small nucleic acid. The positively charged dendrimer can indeed establish electrostatic interactions with the chimeric ferritin internal surface, allowing the formation of a protein-dendrimer binary system. The 4 large triangular openings on the ferritin shell represent a gate for negatively charged small RNAs, which access the internal cavity attracted by the dense positive charge of the dendrimer. This ternary protein-dendrimer-RNA system is efficiently uptaken by acute myeloid leukemia cells, typically difficult to transfect. As a proof of concept, we used a microRNA whose cellular delivery and induced phenotypic effects can be easily detected. In this article we have demonstrat...Continue Reading

References

Jan 17, 2003·The New England Journal of Medicine·Salima Hacein-Bey-AbinaAlain Fischer
Aug 29, 2003·The Journal of Biological Chemistry·N D SonawaneA S Verkman
Nov 19, 2011·Leukemia Research·Jasmin BatlinerMario P Tschan
Jul 7, 2012·Journal of Biomedical Nanotechnology·Mehmet A KilicSema Calis
Oct 15, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Michela BelliniDavide Prosperi
Jul 8, 2015·ACS Nano·Mengxiao Yu, Jie Zheng
Sep 4, 2015·Neural Regeneration Research·Felipe Vidal, Leonardo Guzman
Mar 13, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Marta TruffiSerena Mazzucchelli
Oct 26, 2016·Biochimica Et Biophysica Acta. General Subjects·Lorenzo CalistiAlessandra Bonamore
Nov 15, 2016·Advanced Science·Martin G NussbaumerNico Bruns
Dec 13, 2016·Nanoscale·Valeria de TurrisPaola Baiocco
Jun 1, 2017·Frontiers in Pharmacology·Sonam ChoudharyUmesh Gupta
Aug 24, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Livia Palmerston MendesVladimir P Torchilin
Apr 15, 2018·Leukemia·Michael C Milone, Una O'Doherty
Apr 15, 2018·International Journal of Pharmaceutics·Jong-Won KimHak-Sung Kim
May 23, 2018·International Journal of Pharmaceutics·Jun LiZiyuan Wang
Jul 17, 2018·Advances in Colloid and Interface Science·Laura J FoxWuge H Briscoe
Nov 16, 2018·Pharmaceuticals·Brian Chiou, James R Connor
Mar 10, 2019·Nature Communications·Linda Celeste MontemiglioBeatrice Vallone
Jul 14, 2019·Protein Expression and Purification·Federica PalombariniAlessandra Bonamore
Aug 4, 2019·Biomolecules·Anna JanaszewskaBarbara Klajnert-Maculewicz
Aug 15, 2019·Scientific Reports·Alberto MaconeAlessandra Bonamore
Dec 19, 2019·Journal of Hematology & Oncology·Ye ZhangTing Liu
Jan 15, 2020·Nature Materials·Shrey SindhwaniWarren C W Chan
Jan 19, 2020·Nature Communications·Dongdong WangYanli Zhao
Feb 20, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Federica PalombariniAlessandra Bonamore
Mar 24, 2020·Nature Nanotechnology·Magdalena BorkowskaBartosz A Grzybowski
May 8, 2020·Small·Nan ZhangYanli Zhao
May 14, 2020·Biomolecules·Massimiliano MagroFabio Vianello

❮ Previous
Next ❯

Citations

Aug 21, 2021·Accounts of Chemical Research·Ningning SongMinmin Liang

❮ Previous
Next ❯

Software Mentioned

GraphPad
Image J / Fiji
CytExpert
Prism
Axiovision
Excel
- Prism
ImageJ
Bruker

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

© 2021 Meta ULC. All rights reserved